Guilherme Vilhais, Medical Oncology resident at CUF Oncology, shared on LinkedIn:
“I’m glad to share the first results of our international multicentre S3MI-PT study at ESMO Congress 2026, in Madrid!
S3MI-PT is an ongoing prospective, non-interventional international study aiming to prospectively validate the AJCC pT1a/b subclassification in patients with stage I pure seminoma.
While recruitment is ongoing, our first exploratory analysis focuses on current patterns of adjuvant treatment.
Some key findings from the first 55 patients:
- Despite surveillance being the preferred standard of care, 58.2% of patients received adjuvant chemotherapy, predominantly one cycle of carboplatin.
- Chemotherapy use was more frequent among patients with traditional risk factors, particularly tumour size ≥4 cm (81.5% vs 35.7%) and rete testis invasion (75.0% vs 45.2%).
- These findings suggest that risk-adapted decision-making continues to influence clinical practice, despite the increasing emphasis on surveillance.
Grateful to all colleagues and collaborating centres for their contributions to this ongoing international effort!
ESMO Congress 2026, ePoster 1222eP.”
You can also read: Erika Hamilton: The Clinical Takeaways From ESMO 2026
